Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/10763
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Herbertson, R A | en |
dc.contributor.author | Scarsbrook, A F | en |
dc.contributor.author | Lee, S T | en |
dc.contributor.author | Tebbutt, Niall C | en |
dc.contributor.author | Scott, Andrew M | en |
dc.date.accessioned | 2015-05-16T00:18:52Z | |
dc.date.available | 2015-05-16T00:18:52Z | |
dc.date.issued | 2008-10-23 | en |
dc.identifier.citation | Clinical Radiology 2008; 64(3): 225-37 | en |
dc.identifier.govdoc | 19185652 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/10763 | en |
dc.description.abstract | Positron-emission tomography-computed tomography (PET/CT) is rapidly being integrated into the imaging pathways of several different tumour types, most frequently using the glucose analogue 2- [(18)F]-fluoro-2-deoxy-D-glucose (FDG). Integrated FDG-PET/CT combines functional and anatomical imaging to improve sensitivity and specificity of tumour detection. The aim of this article is to review the established, emerging, and future roles of FDG-PET/CT in the management of patients with colorectal cancer (CRC). | en |
dc.language.iso | en | en |
dc.subject.other | Colonoscopy | en |
dc.subject.other | Colorectal Neoplasms.drug therapy.radionuclide imaging | en |
dc.subject.other | Cost-Benefit Analysis | en |
dc.subject.other | Fluorodeoxyglucose F18.diagnostic use | en |
dc.subject.other | Great Britain | en |
dc.subject.other | Humans | en |
dc.subject.other | Neoplasm Recurrence, Local.radionuclide imaging | en |
dc.subject.other | Neoplasm Staging | en |
dc.subject.other | Neoplasm, Residual | en |
dc.subject.other | Positron-Emission Tomography.economics.methods.trends | en |
dc.subject.other | Radiopharmaceuticals.diagnostic use | en |
dc.subject.other | Radiotherapy Planning, Computer-Assisted | en |
dc.subject.other | Sensitivity and Specificity | en |
dc.subject.other | Tomography, X-Ray Computed.economics.methods.trends | en |
dc.title | Established, emerging and future roles of PET/CT in the management of colorectal cancer. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Clinical radiology | en |
dc.identifier.affiliation | rebecca.herbertson@ludwig.edu.au | en |
dc.identifier.affiliation | Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.doi | 10.1016/j.crad.2008.08.008 | en |
dc.description.pages | 225-37 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/19185652 | en |
dc.type.austin | Journal Article | en |
local.name.researcher | Scott, Andrew M | |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Medical Oncology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Molecular Imaging and Therapy | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.